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Reassessing the role of antitachycardia pacing in fast
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Results from MADIT-RIT
Claudio Schuger, MD, FHRS,* James P. Daubert, MD, FHRS,† Wojciech Zareba, MD, PhD,‡
Spencer Rosero, MD,‡ Patrick Yong, MSEE,x Scott McNitt, MS,‡
Valentina Kutyifa, MD, PhD, FHRS‡
From the *Henry Ford Heart & Vascular Institute, Detroit, Michigan, †Division of Cardiology, Duke
University Medical Center, Durham, North Carolina, ‡Clinical Cardiovascular Research Center,
University of Rochester Medical Center, Rochester, New York, and xBoston Scientiﬁc Corporation, St
Paul, Minnesota.
BACKGROUND In Multicenter Automatic Deﬁbrillator Implantation
Trial – Reduce Inappropriate Therapy (MADIT-RIT), high-rate cutoff
(arm B) and delayed therapy (arm C) reduced the risk of inappropriate implantable cardioverter-deﬁbrillator (ICD) interventions
when compared with conventional programming (arm A); however,
appropriate but unnecessary therapies were not evaluated.

was ATP in 2.8% and shock in 3.8%. In arm C, 4.7% had events,
2.5% were initially treated with ATP and 2.3% with shock, and
the ﬁnal therapy was ATP in 1.4% and shock in 3.3%. The ﬁnal shock
rate was similar in arm A vs arm B (3.5% vs 3.8%; P 5 .800) and in
arm A vs arm C (3.5% vs 3.3%; P 5 .855) despite the marked
discrepancy in initial ATP therapy utilization.

OBJECTIVE The purpose of this study was to assess the value of
antitachycardia pacing (ATP) for fast ventricular arrhythmias
(VAs)  200 beats/min in patients with primary prevention ICD.

CONCLUSION In MADIT-RIT, there was a signiﬁcant reduction in
ATP interventions with therapy delays due to spontaneous termination, with no difference in shock therapies, suggesting that earlier
interventions for VAs  200 beats/min are likely unnecessary, leading to an overestimation of the value of ATP in primary prevention
ICD recipients.

METHODS We compared ATP only, ATP and shock, and shock only
rates in patients in MADIT-RIT treated for VAs  200 beats/min.
The only difference between these randomized groups was the
time delay between ventricular tachycardia detection and therapy
(3.4 seconds vs 4.9 seconds vs 14.4 seconds).
RESULTS In arm A, 11.5% patients had events, the initial therapy
was ATP in 10.5% and shock in 1%, and the ﬁnal therapy was ATP in
8% and shock in 3.5%. In arm B, 6.6% had events, 4.2% were
initially treated with ATP and 2.4% with shock, and the ﬁnal therapy

Introduction
Data from multiple randomized controlled clinical trials, registries, and observational studies indicate that patients at risk
for sudden cardiac death with reduced left ventricular ejection fraction and heart failure derive a survival beneﬁt from
implantable cardioverter-deﬁbrillators (ICDs), either alone
or in conjunction with cardiac resynchronization therapy

KEYWORDS Antitachycardia pacing therapy; ICD; Ventricular
arrhythmia; Ventricular ﬁbrillation; Ventricular tachycardia
(Heart Rhythm 2021;18:399–403) © 2020 Heart Rhythm Society.
This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).

(CRT). However, the occurrence of supraventricular arrhythmias such as atrial ﬁbrillation or ﬂutter or non–life-threatening, nonsustained ventricular tachycardias (VTs) may
result in either inappropriate therapy or prematurely applied,
unnecessary therapy and is a direct consequence of speciﬁc
device parameter programming.1,2 Inappropriate or premature ICD interventions have previously been shown to be
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associated with an impaired quality of life3,4 and potentially
an increased risk of all-cause mortality.1,5
The Multicenter Automatic Deﬁbrillator Implantation Trial
– Reduce Inappropriate Therapy (MADIT-RIT) trial is a largescale randomized study designed to evaluate novel ICD programming to reduce inappropriate therapy in patients with
primary prevention ICD or CRT-D. MADIT-RIT compared
conventional ICD programming with either high-rate therapy
or long delay before therapy delivery and showed that both
high-rate cutoff programming and delayed therapy is associated
with a signiﬁcant reduction in inappropriate ICD therapy.6,7
In this secondary analysis of MADIT-RIT, we aimed to
characterize the rates of different types of appropriate therapies (antitachycardia pacing [ATP], shock, or both) for adjudicated ventricular arrhythmias (VAs) at or above 200 beats/
min by programming arm, rates at which the only difference
between the therapy groups is the time delay between VT
detection and therapy. We hypothesized that progressively
longer delays will result in a reduction in the number of
appropriate ICD therapies, whether ATP or shock, because
of the self-terminating nature of many fast VAs, rendering
early interventions premature and potentially unnecessary.

Methods

Deﬁnitions and study end points
During the total study duration, ﬁrst appropriate ICD therapy
event information was collected from device interrogations
and adjudicated by an independent panel according to prespeciﬁed criteria.7 Appropriate therapy was deﬁned as any
therapy (ATP, shock, or both) delivered for any VAs. Only
episodes with available intracardiac electrograms were
included for appropriate adjudication. Given the memory
limitations of all ICDs, the arrhythmic events are stored chronologically in such a way that the electrograms of prior
events may sometimes be erased from the device memory
to allow the display of the most recent events.
In this analysis, we evaluated the rates of ﬁrst appropriate
therapy  200 beats/min treated with an ATP only, ATP and
shock, and shock only, stratiﬁed by ICD programming arm.
Because we eliminated all VAs events , 200 beats/min,
the only programming difference across the 3 ICD programming arms was therapy delay (Table 1).

Statistical analysis

Study population
MADIT-RIT was a multicenter, randomized, prospective,
controlled clinical trial evaluating patients with approved indications for primary prevention ICD or CRT.8,9 The trial design
and results had been published previously.6,7 MADIT-RIT
was approved by the institutional review boards at the participating centers in accordance with the guidelines of the Declaration of Helsinki. Brieﬂy, patients were randomized to
standard ICD programming  170 beats/min (“arm A”), a
high-rate therapy cutoff  200 beats/min programming strategy (“arm B”), or a prolonged detection duration (60 seconds
170 beats/min and 12 seconds 200 beats/min) strategy
(“arm C”) after a successful implantation of a dual-chamber
ICD or CRT-D device (Table 1). The primary end point of
the study was time to ﬁrst inappropriate ICD therapy (either
ATP and/or shock). MADIT-RIT enrolled 1500 patients, 21
years or older, with ischemic or nonischemic systolic heart
failure. All patients met the guideline criteria for implantation
of primary prevention of ICD or CRT-D.8,9
MADIT-RIT was not prospectively designed to assess the
role of high-rate cutoff programming or therapy delay programming in the frequency of appropriate ICD therapies
Table 1

only; however, because of an extensive adjudication process
of all device interventions, we were able to retrospectively
analyze the behavior of all therapy modalities in VAs above
200 beats/min that received a therapeutic intervention.

First appropriate ICD therapy events  200 beats/min treated
with ATP only, ATP and shock, and shock only are reported
as frequencies and percentages. The rates of ﬁrst appropriate
ATP only and ATP and shock for VAs events  200 beats/
min were displayed by programming arm A (conventional) vs
arm B (high-rate cutoff) vs arm C (delayed therapy programming).
Comparisons of ﬁrst appropriate ATP only and ATP and
shock for VAs events  200 beats/min were performed between conventional arm A vs high-rate arm B and between
conventional arm A vs delayed therapy arm C by using the
c2 test for dichotomous variables. Dichotomous variables,
as two separate tests, since the original study design aimed
to compare these 2 ICD programming arms separately.
All statistical tests were 2-sided, and a P value of ,.05
was considered statistically signiﬁcant. Analyses were performed with SAS version 9.4 (SAS institute, Cary, NC).

Results
MADIT-RIT was a large-scale and well-balanced randomized clinical trial with no signiﬁcant differences between

Programming arms in MADIT-RIT for ventricular arrhythmias . 200 beats/min

Arm A (conventional)

Arm B (high-rate cutoff)

Arm C (therapy delay)

VF zone
200 beats/min, 1 s delay

VF zone
200 beats/min, 2.5 s delay

Quick convert ATP
Shock

Quick convert ATP
Shock

VF zone
200 beats/min, 12 s delay
250 beats/min, 2.5 s delay
Quick convert ATP
Shock

ATP 5 antitachycardia pacing; MADIT-RIT 5 Multicenter Automatic Deﬁbrillator Implantation Trial – Reduce Inappropriate Therapy; VF 5 ventricular ﬁbrillation.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on April 15, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

Schuger et al
Table 2

Antitachycardia Pacing in Fast Ventricular Arrhythmias in Primary Prevention ICD Recipients

401

First appropriate ICD therapy delivered by MADIT-RIT ICD programming arm for ventricular arrhythmias  200 beats/min

Randomized arm

Conventional therapy (n 5 514) High-rate therapy (n 5 500) Delayed therapy (n 5 486) P

Delay before ATP delivery after
detection
First episode—shock (ATP 1 shock,
shock alone)
Shock for rate  250 beats/min
Shock for failed appropriate ATP
First episode—ATP alone
Total ﬁrst episode

1s

2.5 s

12 s

18 (3.5%)

19 (3.8%)

16 (3.3%)

.910

5 (1.0%)
13 (2.5%)
54 (10.5%)
59 (11.5%)

12 (2.4%)
7 (1.4%)
21 (4.2%)
33 (6.6%)

11 (2.3%)
5 (1.0%)
12 (2.5%)
23 (4.7%)

.178
5.153
,.0001
.0002

ATP 5 antitachycardia pacing; ICD 5 implantable cardioverter-deﬁbrillator; MADIT-RIT 5 Multicenter Automatic Deﬁbrillator Implantation Trial – Reduce
Inappropriate Therapy.

patient clinical characteristics across the different ICD programming arms.6 In this analysis, we evaluated only VAs
events  200 beats/min for which the only programming difference across the 3 ICD programming arms was therapy
delay (Table 1).

of 21 events); and in arm C, it is 58.3% (7 of 12 events). Since
ATP was applied in some VAs that were destined to
self-terminate as mentioned above, the perceived efﬁcacy
of ATP in patients with primary prevention ICD may be overstated as well when applied prematurely.

Rates of ATP only, ATP and shock, and shock only
appropriate therapy events ‡ 200 beats/min

Discussion

In MADIT-RIT arm A with conventional ICD programming,
59 patients (11.5%) had VAs  200 beats/min; 54 of them
(10.5%) were initially treated with ATP and 5 of them
(1%) with shock (VAs  250 beats/min at onset). The ﬁnal
therapy, deﬁned as the therapy modality preceding the return
to normal rhythm, was ATP in 41 patients (8%) and shock in
18 patients (3.5%). In arm B, 33 patients (6.6%) had VAs 
200 beats/min; 21 (4.2%) were initially treated with ATP and
12 (2.4%) with shock (VAs  250 beats/min at onset). The
ﬁnal therapy was ATP in 14 patients (2.8%) and shock in
19 patients (3.8%). In arm C, 23 patients (4.7%) had VAs
 200 beats/min; 12 (2.5%) were initially treated with ATP
and 11 (2.3%) with shock (VAs  250 beats/min at onset).
The ﬁnal therapy was ATP in 7 patients (1.4%) and shock
in 16 patients (3.3%). The ﬁnal shock event rate was similar,
3.5%, 3.8%, and 3.3%, in arms A, B, and C, while ATP therapy was signiﬁcantly reduced between therapy arms,
revealing the inﬂuence of incrementally delayed therapy on
the incidence of ATP delivery (Table 2 and Figure 1).
The proportion of patients who received an appropriate
ICD therapy for VAs  200 beats/min in MADIT-RIT was
reduced by up to 62% when comparing the conventional
ICD programming arm (arm A) with the delayed therapy
ICD programming arm (arm C). When analyzed by the 2
types of ICD therapy, we ﬁnd that this decrease was driven
almost entirely by a 78% reduction in the delivery of ATP.
Because MADIT-RIT was a large and well-balanced randomized study, this outcome is likely the result of longer
therapy delays across study arms, allowing even longer “nonsustained” VAs to self-terminate before therapy delivery as
illustrated in Figure 2.
Moreover, it is interesting to note that the apparent ATP
efﬁcacy across ICD programming arms in MADIT-RIT appears to decrease (Figure 2). In arm A, the ATP success
rate is 75.9% (41 of 54 events); in arm B, it is 66.7% (14

In this retrospective analysis of the MADIT-RIT cohort with
appropriate therapies at or above 200 beats/min, we clearly
demonstrated that increasing therapy delays resulted in
marked reductions in the utilization of ATP therapies as the
time to therapy was increased from 3.4 seconds (arm A) to
4.9 seconds (arm B) to 14.4 seconds (arm C). Furthermore,
the 2 types of ICD therapies (ATP or shock) revealed that
the incidence of appropriate shocks delivered for VAs 
200 beats/min was similar across all 3 arms with no signiﬁcant differences. The incidence of appropriate ATP in the
conventional ICD programming arm was 18% compared
with 5% in those with high-rate therapy programming and
2% in those with delayed therapy programming. These ﬁndings altogether suggest a limited value of ATP for treating
fast VAs  200 beats/min with longer detection delays in a
population with primary prevention ICD as opposed to
high ATP efﬁcacy in populations with secondary prevention.4
The only plausible explanation for the above observations
is that as therapy delay is increased, many of the VAs selfterminate. The importance of this observation is 2-fold: (1)
The value of ATP effectiveness in a population with primary
prevention could be overestimated in light that with long
therapy delays, many VAs are in fact self-terminating
without an ATP intervention. (2) Relatively long therapy delays are well tolerated without an increase in cardiovascular
morbidity while enormously reducing the frequency of unnecessary interventions, mainly ATP.
Interestingly, an analysis of mortality in MADIT-RIT10
revealed a statistically signiﬁcant association between inappropriate ATP and all-cause mortality while no association
was found between appropriate ATP and all-cause mortality.
However, an association does not necessarily imply causality, and further investigation into ATP and its value in a population with primary prevention ICD is warranted.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on April 15, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

402

Heart Rhythm, Vol 18, No 3, March 2021

Figure 1 The rate of ﬁrst appropriate implantable cardioverter-deﬁbrillator therapies (antitachycardia pacing [ATP] only, ATP and shock, and shock only) for
ventricular arrhythmias  200 beats/min in Multicenter Automatic Deﬁbrillator Implantation Trial – Reduce Inappropriate Therapy by programming arms.

The Pacing Fast Ventricular Tachycardia Reduces Shock
Therapies (PainFREE Rx II) study11 is the only multicenter
prospective randomized study that has previously evaluated
the efﬁcacy of ATP for rapid VAs. Patients were randomized
to receive ATP or shocks only, with both arms programmed
to detection of 18 of 24 fast intervals at a rate cutoff of 188
beats/min. This study enrolled patients from January 2001
to March 2002 and included a mix of patients with mainly
secondary indications but ceased enrollment before the era

of primary prevention ICD indications. More than one-third
of episodes in the shock arm self-terminated during a median
capacitor charge time of 3.3 seconds, leading to the possibility that a longer detection time could have further reduced the
rate of ATP or shocks for VTs. Other studies that examined
the role of therapy delays, such as the Primary Prevention Parameters Evaluation study11 and the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III
(ADVANCE-III) study,12 had considerably shorter therapy

Figure 2 The rate of successful and failed antitachycardia pacing (ATP) across Multicenter Automatic Deﬁbrillator Implantation Trial – Reduce Inappropriate
Therapy programming arms for ventricular arrhythmias  200 beats/min. NSVT 5 non-sustained ventricular tachycardia; Pct 5 percent.
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delays (an effective delay of w9 seconds) and included patients with both primary and secondary prevention indications. In a subanalysis of ADVANCE-III13 that speciﬁcally
tried to look at the value of ATP over a long detection interval, the authors ﬁnd an efﬁcacy of only 52% in the long detection arm, similar to our ﬁnding when compared to the
standard detection interval arm. However, the authors
ascribed an additive value of ATP over long detections on
the basis of a hypothetical scenario that all tachycardias
that terminated during charging did so because of ATP at
the time of charging without considering the possibility of
self-termination. Moreover, the authors acknowledge that
ATP was less effective in patients with primary prevention
as opposed to patients with secondary prevention. As is the
case with our study, there was not statistically signiﬁcant difference in the number of shocks delivered for VAs between
both arms of ADVANCE III.
The studies previously mentioned evaluated ATP interventions with the implicit assumption that termination of
those events was the result of the intervention. However,
application of longer delays in this study rendered up to
78% of ATP episodes unnecessary. This appropriately highlights that the risk/proﬁle beneﬁt of ATP in primary prevention ICD recipients should be reexamined in a prospective
randomized trial given that the presumption of efﬁcacy in a
pure primary prevention cohort remains unproven.
It is also worth mentioning that the number of patients
needing shock therapy was not statistically different across
ICD programming arms despite a massive reduction in
ATP events, suggesting that ATP-induced accelerations leading to sustained rapid VAs requiring shocks are uncommon, a
ﬁnding also reported in the ADVANCE III subanalysis.

Limitations
This analysis from MADIT-RIT is retrospective, and the
usual caveats about hypothesis-generating data analysis
apply. Moreover, given the small number of patients in
MADIT-RIT with delayed therapy who had ATP events, a
substantially larger prospective randomized controlled trial
will be necessary to conﬁrm this hypothesis.

Conclusion
We conclude from the data of this secondary analysis of
MADIT-RIT that the value of ATP in patients with primary
prevention ICD may have been overestimated. ATP success
as previously reported in other studies potentially includes a
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large proportion of patients who receive unnecessary ATP for
nonsustained VT destined to terminate spontaneously anyway.
The ultimate value of ATP in a pure primary prevention
population remains speculative.
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